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Over the last 20 years, the cure rates for childhood cancer
have improved from 20% to an overall survival of65% while
in some groups they are as high as 90% (Stiller & Bunch,
1990; Birch et al., 1988). These dramatic improvements have
made it possible to predict, with some confidence, cure for
the majority of children who survive for 5 years from diag-
nosis without evidence of recurrence. Late relapses do occur.
They are more common in brain tumours, Hodgkin's Disease
and Ewing's Tumour than the other common childhood
malignancies, and acute lymphoblastic leukaemia (ALL) is a
special case with more than 50% of 5-year survivors diag-
nosed before 1971, ultimately dying of recurrent disease
(Hawkins et al., 1990). More intensive initial treatment which
is common in the present era is likely to reduce these late
relapses.
The implications of the survival of these patients are that
by the beginning of the 21st Century 1 in 1000 young adults
will be survivors of childhood cancer and very few of them
will be free of long-term problems due to their initial treat-
ment. Follow-up of these patients is therefore essential
throughout adult life.
Retrospective assessment and investigation of the current
cohort of survivors of treatment given in the 1950s and 60s
reveals many problems which vary according to the treat-
ment given. Most of these survivors have been cured by the
use of surgery and radiotherapy in the case of solid tumours
and non-intensive chemotherapy in the patients treated for
leukaemia. The radiotherapy used in the early days was
usually delivered from othovoltage machines and surgery was
often more extensive than would be advised today. Never-
theless these patients give us a very good baseline for study
and have contributed a great deal to our knowledge of the
unwanted but often inevitable results of successful treatment
(Green, 1989). Radiotherapy produces late consequences of
variable degree whenever it is used in childhood. These con-
sequences are frequently enhanced by chemotherapy and
evidence is now accumulating of the late toxicity of many
cytotoxic drugs when used alone and in combination pro-
tocols.
Musculo- skeletal problems are largely caused by radiation
damage to the micro vasculature of the epiphyseal growth
zone (Rubin et al., 1959). This can lead to spinal shortening
(Probert et al., 1973), scoliosis and asymmetry to limb length.
Slipped femoral epiphysis also occur in children who receive
pelvic irradiation involving the acetabulum in the field (Lib-
schitz & Ederkin, 1981) and avascular necrosis of the femoral
and humoral heads is described (Mould & Adam, 1983).
The consequences of treatment on endocrine function have
been extensively reviewed by Shalet (Shalet, 1989). This dys-
function includes the effects of radiation to the brain causing
growth hormone failure or loss of normal pulsitile growth
hormone production, thyroid damage leading to overt or
compensated hypothyroidism and thyroid tumours and
gonadal damage giving rise to both germ cell ablation and
sex hormone failure. All of these effects require investigation
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and treatment if optimal growth and development is to be
achieved and it is essential that these patients are followed
through puberty and beyond in order to ensure appropriate
replacement therapy is given. A proportion of patients with
gonadal dysfunction will have increased levels of lutenising
and follicle stimulating hormones which can give risk to early
puberty which, if untreated will lead to premature epiphyseal
fusion and eventual short stature (Quigley et al., 1989). Early
menopause is also well recognised in this group of patients
and is due to loss of germ cells secondary to irradiation or
cytotoxic agents (Wallace et al., 1989).
Hypertension can occur usually caused by direct radiation
to the kidneys and the tolerance dose of the kidneys is
reduced if radiation is given in conjunction with enhancing
cytotoxic agents (Arneil et al., 1974). Direct cardiotoxicity is
caused by anthracyclines, especially adriamycin, and also by
cyclophosphamide. The severity ofthe damage is dose related
and also dependent on dose rate (Torti et al., 1983; Legha et
al., 1982). Most studies suggest that cummulative doses of
less than 500mgm-2 of adriamycin are rarely associated
with clinical symptoms and signs however endomyocardial
biopsy shows damage after even a single dose and late onset
cardiac failure in circumstances of stress are now being
reported (Steinhertz et al., 1987). Direct radiation damage to
the heart has been investigated following treatment for
Hodgkin's disease and while damage is difficult to demon-
strate in life when modern radiation techniques have been
used, pericardial thickening was shown (Green et al., 1987).
Pathology studies have demonstrated pericardial thickening
and coronary vascular damage in young patients at autopsy
when there was no evidence of cardiac dysfunction in life.
Causes of late death in patients treated for childhood cancer
reported by Hawkins et al., 1990 include eight in whom
death was due to myocardial infarction. They also report
seven patients who died from cerebravascular accidents
before the age of 43 years.
Vision can be impaired either by damage to the retina or
optic nerve or more frequently by the development of radia-
tion induced cataract and kerato conjunctivitis (Heyn et al.,
1986). Hearing is at particular risk following treatment with
cisplatinum (Sexauer et al., 1985). Some of the most widely
described long-term effects of treatment are the neuro-
psychological sequelae, these are almost certainly limited to
children who have received cranial irradiation for brain
tumours or acute lymphoblastic leukaemia (Peckham et al.,
1988). Cognitive function is most severely impaired in child-
ren irradiated under the age of 2 years and now studies are
underway in which chemotherapy is given until children are
at least 3 years of age in the case of brain tumours and to
delay or omit radiation giving intrathecal or high dose
methotrexate instead of the case of ALL. A recent review of
Eiser (Eiser 1991) describes the difficulties encountered in
attempting to actually delineate the learning problems of
these children. While it is clear in some studies that specific
problems do exist with particular deficits in memory and
motor skills, there are other compounding factors such as
variable absences from school, altered motivation of child
and family and teachers attitudes to children with cancer in
the classroom. Many paediatric oncology centres now rou-
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tinely liaise with schools in order to encourage extra tuition
where indicated and to give accurate information regarding
prognosis to teaching staff. The Cancer Research Campaign
Education & Child Studies Research Group have produced a
booklet to help teachers understand. Home tuition is pro-
vided during periods of profound immunosuppression when
school attendance is not possible and as a way of re-
establishing routine and return to school.
There is clear evidence of an increased frequency of second
primary neoplasms in children treated for malignancy (Li et
al., 1975; Hawkins et al., 1987; Meadows et al., 1985). The
majority of these are skin cancers and bone and soft tissue
sarcomas occurring in the previously irradiated area but now
second tumours are arising in patients who have not received
irradiation. Some of the cases have a known genetic predis-
position, e.g. retinoblastoma (Abramson et al., 1979) and
neurofibromatosis. Others have presumably suffered chromo-
somal damage. At present the drugs most frequently
implicated are the alkylating agents and when given in com-
bination with radiation the risk is increased.
Even when children are cured of their cancer problems
remain, life insurance, and mortgages are often refused with-
out increased premiums. Employers are often discriminatory.
There is a continuing ignorance in the lay public and indeed
in the medical and para medical professions with regard to
long term prognosis and to the potential of these young
adults. This reduces self-esteem and causes ongoing distress
to patients who have already suffered much trauma.
Yet another late problem is now beginning to emerge -
that of litigation. In the past it is true to say that families
were ill informed of potential late toxicity and the major
problems discussed here. Some now feel it is their right to
obtain compensation for the child. Until the 1970s some of
the consequences were unrecognised and could not have been
predicted. The numbers of long term survivors were small
and data on their status sparse. This is no longer so and it
behoves all clinicians to be clear from the outset regarding
what the future might hold (Miller, 1988).
The main aim of treatment of childhood cancer is to cure
the patient and to allow them to continue to grow and
develop within a normal environment in preparation for a
useful and productive adult life. This can be achieved but not
without cost to the child, family and community. In order to
minimise the cost absolute honesty is necessary from the time
of diagnosis so that problems can be anticipated, and dealt
with appropriately. Inevitable toxicity must be accepted and
minimised by alteration in treatment providing cure is not
jeopardised. Lifetime follow-up is essential for all these
patients but they themselves are the best monitors of their
health and they must be guided to accept responsibility and
to be the vanguard of educators of the profession and the
public. They must not feel the cost of cure has been too
great.
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